Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07518186) titled 'A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma' on April 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Janssen Research & Development, LLC
Condition:
Multiple Myeloma
Intervention:
Drug: JNJ-79635322
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: June 8, 2026
Target Sample Size: 700
To know more, visit https://clinicaltrials.gov/study/NCT07518186
Published by HT Digital Content ...